Company family
Hcs: medicine shortages
As of 2 Nov 2026, 11 Hcs products have a reported shortage across 2 countries, covering 8 medicines.
Where
Which therapeutic classes
Why, compared with all companies
Manufacturing problems point to the company's own supply chain; increased demand often follows a competitor's shortage or a demand shock.
Latest changes
All changesNo changes recorded yet. Changes are tracked from our daily snapshots.
Open shortages over time
Products short per day in the 5 countries tracked since 31 Oct 2026, from our daily snapshots. The history lengthens every day.
When its current shortages began
Against its peers
Breadth vs depth
Further right: more products short. Higher: more different medicines affected.
Medicines short
Download CSV| Medicine | Where this company is short | Products | Earliest start | Main reason | Short anywhere |
|---|---|---|---|---|---|
| Valsartan and Diuretics | 3 | 14 Jul 2025 | Commercial decision or withdrawal | 7/16 | |
| Memantine | 2 | 3 Aug 2026 | Manufacturing problem | 8/16 | |
| Atorvastatin and Ezetimibe | 1 | not given | Manufacturing problem | 6/16 | |
| Pregabalin | 1 | 1 May 2026 | Manufacturing problem | 11/16 | |
| Rosuvastatin | 1 | 22 Oct 2026 | Manufacturing problem | 12/16 | |
| Rosuvastatin and Ezetimibe | 1 | 22 Oct 2026 | Manufacturing problem | 6/16 | |
| Sitagliptin | 1 | 22 Oct 2026 | Manufacturing problem | 8/16 | |
| Teriflunomide | 1 | 21 Dec 2026 | Manufacturing problem | 4/16 |
Shortage data describes supply, not company finances. A shortage can mean lost sales for the supplier or extra demand for its competitors. Nothing here is investment advice; tickers are for identification only and may be out of date.